At the American College of Rheumatology (ACR)’s State-of-the-Art (SOTA) Symposium, held last week in Chicago, Illinois, Judith James, MD, PhD, chair of arthritis and clinical immunology at Oklahoma Medical Research Foundation, presented a talk on precision medicine in rheumatology.
At the American College of Rheumatology's (ACR) 2018 State-of-the-Art (SOTA) Symposium, held last week in Chicago, Illinois, Judith James, MD, PhD, chair of arthritis and clinical immunology at Oklahoma Medical Research Foundation, presented a talk on precision medicine in rheumatology.
James opened her talk by highlighting the differences between precision medicine and personalized medicine. James explained, “Precision medicine is understanding a disease at a deeper level in order to develop more targeted therapies, while personalized medicine is when therapeutics are synthesized for a specific individual.”
James went on to discuss a few steps toward precision medicine already that exist in rheumatology, such as the following:
“Historically, rheumatologists have the highest number of FDA-approved biomarkers for tests in rheumatology compared to all other medicine specialties,” said James.
Although some forms of precision medicine exist in rheumatology already, there is still a long way to go. “We need better information to help us select the right drug, at the right dose, at the right time, in the right patient, and that will hopefully optimize outcomes.”
In addition, James explained how to optimize biologic drugs’ efficacy in RA, citing different factors and their respective effects on treatment, such as increased body mass index (BMI), smoking, the presence of antibodies, and concurrent methotrexate or other disease-modifying anti-rheumatic drugs (DMARD).
Increased BMI leads to worse outcomes in RA, a problem that can be avoided through diet-induced weight loss of 5% to 10%, which has been found to improve disease activity without needing to increase DMARD dosing. In addition, smoking leads to worse outcomes with increased extra-articular manifestations, as well as adversely affecting anti—tumor necrosis factor therapy. The presence of auto-antibodies is associated with better efficacy of rituximab and abatacept in seropositive disease. Finally, James noted, all biologics perform better when used together with methotrexate.
In closing her talk, James discussed different precision medicine factors currently being investigated for their potential use in rheumatology:
“We’re going to different types of interactions with different kinds of health professionals that we haven’t historically used in rheumatology, like molecular pathologists, genetic counselors, and health coaches,” said James.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Infliximab Biosimilar Switch Due to Flare Risk: Monitoring Patients Is Crucial for Pharmacists
June 5th 2025Switching from reference infliximab to biosimilars (infliximab-abda and infliximab-dyyb) for rheumatic diseases may lead to treatment delays and a higher risk of disease flares, particularly when the switch is mandated by insurance.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
British Columbia’s Biosimilar Policy Shows No Impact on Hospital Visits
May 28th 2025Despite a dramatic shift toward biosimilar use following British Columbia’s policy, researchers found no rise in hospital visits or complications, underscoring the real-world reliability of etanercept biosimilars in managing inflammatory arthritis.